ECUR 506
Alternative Names: ECUR-506; GTP-506; iECURE-OTCLatest Information Update: 06 Sep 2026
At a glance
- Originator iECURE
- Class Gene therapies
- Mechanism of Action Gene transference; Ornithine carbamoyltransferase replacements
-
Orphan Drug Status
Yes - Ornithine carbamoyltransferase deficiency disease
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Ornithine carbamoyltransferase deficiency disease
- Preclinical Citrullinemia
- Research Phenylketonuria
Most Recent Events
- 27 Aug 2026 Updated efficacy, pharmacodynamics and adverse events data from a phase I/II trial in Ornithine carbamoyltransferase deficiency disease released by iECURE
- 10 May 2026 Early research in Phenylketonuria in USA (Parenteral) prior to May 2026 (iECURE Pipeline, May 2026)
- 10 May 2026 Preclinical trials in Citrullinemia in USA (Parenteral) prior to May 2026 (iECURE Pipeline, May 2026)